Hematopoietic stem cell transplantation for neuroblastoma
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e296Keywords:
Neuroblastoma, Stem Cell Transplantation, High-risk Disease, Pediatric. ConsensusAbstract
High-risk neuroblastoma requires intensive multimodal therapy, and autologous hematopoietic stem cell transplantation (auto-HCT) remains a key component of consolidation treatment. This consensus document updates the 2021 Brazilian recommendations for neuroblastoma transplantation, focusing on indications, eligibility criteria, conditioning regimens, and the role of single versus tandem auto-HCT. Post-transplant consolidation strategies, including radiotherapy, isotretinoin, and anti-GD2 immunotherapy, as well as transplant-related toxicities and follow-up, are reviewed. The role of transplantation in relapsed or refractory disease is also addressed. These recommendations aim to support standardized, evidence-based management of children with high-risk neuroblastoma in the Brazilian setting.
References
1. Nong J, Su C, Li C, Wang C, Li W, Li Y, Chen P, Li Y, Li Z, She X, Yuan Z, Liu S, Chen C, Liao Q, Luo Y, Shi B. Global, regional, and national epidemiology of childhood neuroblastoma (1990-2021): a statistical analysis of incidence, mortality, and DALYs. EClinicalMedicine. 2024;79:102964. https://doi.org/10.1016/j.eclinm.2024.102964
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s cancer myeloablative therapy and ASCT with/without anti-GD2 immunotherapy in high-risk neuroblastoma 157 group. N Engl J Med. 1999;341:1165–73. https://doi.org/10.1056/NEJM199910143411601
3. Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388(14):1284–95. https://doi.org/10.1056/NEJMoa2210859
4. Breviglieri CNM, Michalowski MB, Gregianin L, Castro Junior CG. Hematopoietic stem cell transplantation for neuroblastoma. J Bone Marrow Transplant Cell Ther. 2021;2(4):136–9. https://doi.org/10.46765/2675-374X.2021v2n4p136
5. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau- Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN). Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18(4):500–14. https://doi.org/10.1016/S1470-2045(17)30070-0
6. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27(7):1007–13. https://doi.org/10.1200/JCO.2007.13.8925. Epub 2009 Jan 26. Erratum in: J Clin Oncol. 2014;32(17):1862–3.
7. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179–89. https://doi.org/10.1158/1078-0432.CCR-20-3909
8. PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ®): Health Professional Version. 2024 Nov 12. In: PDQ Cancer Information Summaries. Bethesda: National Cancer Institute; 2002.
9. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746–55. https://doi.org/10.1001/jama.2019.11642
10. Children’s Oncology Group. NCT03126916: ANBL1531: Phase III Study of 131I-MIBG or ALK inhibitor therapy added to intensive therapy for children with newly diagnosed high-risk neuroblastoma. Clinical Trials. 2025. Available from: https://clinicaltrials.gov/study/NCT03126916
11. SIOPEN. NCT03165292: VERITAS: An international multicenter phase II randomised trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemotherapy. ClinicalTrials. 2025. Available from: https://clinicaltrials.gov/study/NCT03165292
12. SIOPEN High Risk Neuroblastoma Study 2 (HR-NBL2). ClinicalTrials.gov identifier: NCT04221035. Bethesda: U.S. National Library of Medicine; 2020. Available from: https://clinicaltrials.gov/study/NCT04221035
13. Hudda Z, Webster A, Anderson E, Badia P, Bagatell R, Bhar S, Bidgoli A, Boyd K, Chaudhury S, Cisneros GS, Craddock J, Davies SM, Desai AV, Drobatz L, Dvorak CC, Elkus H, Fabrizio VA, Foster JH, Fraint E, Freedman JL, Galvez J, Garcia M, Haight A, Higham C, Jodele S, Kamat A, Kaviany S, Lehmann L, Leung K, Lind KT, Llaurador G, Kapadia M, Khazal S, Massi K, Mormann M, Pater L, Rangarajan HG, Rotz S, Sabulski A, Sartain S, Schoettler ML, Sokol E, Streby KA, Stein M, Verneris MR, Weiss BD, Yazdani S, Zheng D, Dandoy CE. Acute toxicities and early outcomes of tandem autologous stem cell transplantation in pediatric high-risk neuroblastoma: a multicenter study. Transplant Cell Ther. 2025:S2666-6367(25)01525-8. https://doi.org/10.1016/j.jtct.2025.10.022
14. Yanik G. Updates on transplant for high-risk neuroblastoma. Pediatric Session: Updates in Neuroblastoma Therapy. In: Tandem Meetings 2025. 2025.
15. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantationassociated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023;29(3):151–63. https://doi.org/10.1016/j.jtct.2022.11.015
16. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, Lankester A, Locatelli F, Pagliuca A, Peters C, Richardson PG, Schulz AS, Sedlacek P, Stein J, Sykora KW, Toporski J, Trigoso E, Vetteranta K, Wachowiak J, Wallhult E, Wynn R, Yaniv I, Yesilipek A, Mohty M, Bader P. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138–45. https://doi.org/10.1038/bmt.2017.161
17. Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N. Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma. J Pediatr Hematol Oncol. 2015;37(3):175–80. https://doi.org/10.1097/MPH.0000000000000264
18. Makimoto A, Fujisaki H, Matsumoto K, Takahashi Y, Cho Y, Morikawa Y, Yuza Y, Tajiri T, Iehara T. Retinoid therapy for neuroblastoma: historical overview, regulatory challenges, and prospects. Cancers (Basel). 2024;16(3):544. https://doi.org/10.3390/cancers16030544
19. Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol. 2024;42(1):90–102. https://doi.org/10.1200/JCO.22.02875
20. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56(4):578–83. https://doi.org/10.1002/pbc.22693
21. Prete A, Lanino E, Saglio F, Biffi A, Calore E, Faraci M, Rondelli R, Favre C, Zecca M, Casazza G, Porta F, Luksch R, Cesaro S, Rabusin M, Parasole R, Mura RM, Lo Nigro L, Leardini D, Pagliara D, Locatelli F, Fagioli F; AIEOP-BMT Group. Phase II study of allogeneic hematopoietic stem cell transplantation for children with high-risk neuroblastoma using a reduced-intensity conditioning regimen: results from the AIEOP trial. Transplant Cell Ther. 2024;30(5):530.e1–e8. https://doi.org/10.1016/j.jtct.2024.03.002
22. Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, Iehara T, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T; Japan Children’s Cancer Group (JCCG) Neuroblastoma Committee (JNBSG). Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. Jpn J Clin Oncol. 2022;52(5):486–92. https://doi.org/10.1093/jjco/hyac007
23. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant. 2013;48(8):1056–64. https://doi.org/10.1038/bmt.2012.284
24. Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P. Haploidentical stem cell transplantation for refractory/relapsed neuroblastoma. Biol Blood Marrow Transplant. 2018;24(5):1005–12. https://doi.org/10.1016/j.bbmt.2017.12.805
25. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma patients’ KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children’s Oncology Group. Clin Cancer Res. 2018;24(1):189–96. https://doi.org/10.1158/1078-0432.CCR-17-1767
26. Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022;19(8):515–33. https://doi.org/10.1038/s41571-022-00643-z
27. Children’s Oncology Group. ANBL0532: Phase III randomized trial of single vs. tandem myeloablative consolidation therapy for high-risk neuroblastoma [protocol]. Version 4A. Seattle: Children’s Oncology Group; 2011.
28. Clement SC, van Eck-Smit BL, van Trotsenburg AS, Kremer LC, Tytgat GA, van Santen HM. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance. Pediatr Blood Cancer. 2013; 60(11):1833–8. https://doi.org/10.1002/pbc.24681
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Carla Nolasco Monteiro Breviglieri, Nathália da Silva Halley Neves, Mariana Bohns Michalowski, Augusto Oliveira Silva, Patrícia Shimoda Ikeuti, Ainá Henriques Melgaço, Simone de Castro Resende Franco, Cláudio Galvão de Castro Júnior, Adriana Seber
This work is licensed under a Creative Commons Attribution 4.0 International License.
